









市场行情
/
股票
/
nasdaq-bntc
/

Benitec Biopharma Inc

BNTC

12.960USD

+0.610+4.94%

收盘 12/23, 16:00（美东）报价延迟15分钟

340.21M总市值

亏损市盈率 TTM



Benitec Biopharma Inc

12.960

+0.610+4.94%

概览公司财务分析

概览

公司

财务

分析

关于 Benitec Biopharma Inc 公司

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Benitec Biopharma Inc简介



公司代码BNTC

公司名称Benitec Biopharma Inc

上市日期Jul 11, 2012

CEOBanks (Jerel A)

员工数量19

证券类型Ordinary Share

年结日Jul 11

公司地址3940 Trust Way

城市HAYWARD

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94545

电话15107800819

网址https://benitec.com/

公司代码BNTC

上市日期Jul 11, 2012

CEOBanks (Jerel A)

Benitec Biopharma Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Megan Joan Boston

Chief Financial Officer, Executive Director, Secretary

25.93K

Ms. Sophie Mukadam

Chief Operating Officer

6.02K

Mr. Peter Damian Francis

Independent Director

297.00

Buchi (J Kevin)

Independent Director

Mr. Kishan (Kishen) Mehta

Independent Director

Dr. Sharon Mates, Ph.D.

Independent Director

Ms. Irina Koffler

Managing Director

Dr. Jerel A. Banks, M.D., Ph.D.

Executive Chairman of the Board, Chief Executive Officer

Mr. Edward F. Smith

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Megan Joan Boston

Chief Financial Officer, Executive Director, Secretary

25.93K

Ms. Sophie Mukadam

Chief Operating Officer

6.02K

Mr. Peter Damian Francis

Independent Director

297.00

Buchi (J Kevin)

Independent Director

Mr. Kishan (Kishen) Mehta

Independent Director

Dr. Sharon Mates, Ph.D.

Independent Director

收入明细

单位: USD更新时间: 7月6日周日

FY2023

FY2022

FY2021

FY2019

业务USD

名称

营收

占比

Licensing revenue

75.00K

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Licensing revenue

75.00K

0.00%

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

Suvretta Capital Management, LLC

33.54%

Janus Henderson Investors

8.60%

Franklin Advisers, Inc.

7.65%

Adage Capital Management, L.P.

5.83%

RA Capital Management, LP

5.46%

其他

38.92%

持股股东

占比

Suvretta Capital Management, LLC

33.54%

Janus Henderson Investors

8.60%

Franklin Advisers, Inc.

7.65%

Adage Capital Management, L.P.

5.83%

RA Capital Management, LP

5.46%

其他

38.92%

股东类型

持股股东

占比

Hedge Fund

44.05%

Investment Advisor/Hedge Fund

19.90%

Investment Advisor

11.78%

Venture Capital

5.46%

Corporation

2.20%

Research Firm

0.61%

Individual Investor

0.53%

Bank and Trust

0.04%

Insurance Company

0.02%

其他

15.40%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

104

27.71M

70.75%

+3.33M

2025Q3

104

24.38M

91.26%

+455.37K

2025Q2

100

23.88M

84.92%

+1.54M

2025Q1

22.35M

78.36%

+2.34M

2024Q4

20.11M

70.30%

+3.66M

2024Q3

14.59M

41.10%

+7.39M

2024Q2

7.24M

58.15%

+2.08M

2024Q1

1.32M

57.31%

-243.94K

2023Q4

1.24M

60.74%

-70.36K

2023Q3

1.31M

59.46%

+42.18K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Suvretta Capital Management, LLC

9.88M

37.62%

Jun 30, 2025

Janus Henderson Investors

2.90M

11.06%

-16.16K

-0.55%

Jun 30, 2025

Franklin Advisers, Inc.

2.70M

10.29%

-159.28K

-5.57%

Jun 30, 2025

Adage Capital Management, L.P.

1.97M

7.51%

Jun 30, 2025

HBM Partners AG

1.04M

3.97%

+200.27K

+23.80%

Dec 31, 2024

The Vanguard Group, Inc.

969.17K

3.69%

+642.13K

+196.35%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

661.64K

2.52%

+477.75K

+259.80%

Jun 30, 2025

Nantahala Capital Management, LLC

838.10K

3.19%

Jun 30, 2025

Nemean Asset Management, LLC

746.32K

2.84%

+648.12K

+659.98%

Apr 22, 2024

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Health Care ETF

1.08%

iShares Neuroscience and Healthcare ETF

0.53%

iShares Micro-Cap ETF

0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

0.01%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Simplify Health Care ETF

占比1.08%

iShares Neuroscience and Healthcare ETF

占比0.53%

iShares Micro-Cap ETF

占比0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0.01%

Global X Russell 2000 ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

占比0.01%

ProShares UltraPro Russell2000

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

公告日期

类型

比率

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

常见问题

Benitec Biopharma Inc的前五大股东是谁？



Benitec Biopharma Inc 的前五大股东如下：
Suvretta Capital Management, LLC持有股份：9.88M，占总股份比例：37.62%。
Janus Henderson Investors持有股份：2.90M，占总股份比例：11.06%。
Franklin Advisers, Inc.持有股份：2.70M，占总股份比例：10.29%。
Adage Capital Management, L.P.持有股份：1.97M，占总股份比例：7.51%。
HBM Partners AG持有股份：1.04M，占总股份比例：3.97%。